MLTX - MoonLake Immunotherapeutics - Ordinary Shares - Class A
IEX Last Trade
46.725
-0.755 -1.616%
Share volume: 188,560
Last Updated: Fri 30 Aug 2024 09:59:54 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$47.48
-0.76
-1.59%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-5.99%
1 Month
13.40%
3 Months
14.01%
6 Months
-17.64%
1 Year
-16.73%
2 Year
484.88%
Key data
Stock price
$46.72
DAY RANGE
N/A - N/A
52 WEEK RANGE
$35.11 - $64.98
52 WEEK CHANGE
-$0.13
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO:
Region: US
Website:
Employees: 14
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website:
Employees: 14
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
moonlake immunotherapeutics ag is a clinical-stage biopharmaceutical company leveraging revolutionary nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
Recent news